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Abstract
Purinergic receptors are important for the regulation of inflammation, muscle contraction, neurotransmission and nociception. Extracellular
ATP and its metabolites are the main ligands for these receptors. Occasional reports on beneficial results of ATP administration in human
and animal studies have suggested the bioavailability of oral ATP supplements. We investigated whether prolonged daily intake of oral ATP
is indeed bioavailable. Thirty-two healthy subjects were randomised to receive 0, 250, 1250 or 5000 mg ATP per d for 28 d by means of
enteric-coated pellets. In addition, on days 0 and 28, all thirty-two subjects received 5000 mg ATP to determine whether prolonged admin-
istration would induce adaptations in the bioavailability of ATP. ATP supplementation for 4 weeks did not lead to changes in blood or
plasma ATP concentrations. Of all ATP metabolites, only plasma uric acid levels increased significantly after the administration of
5000 mg of ATP. Prolonged administration of ATP was safe as evidenced from liver and kidney parameters. We conclude that oral admin-
istration of ATP only resulted in increased uric acid concentrations. On the basis of these findings, we seriously question the claimed
efficacy of oral ATP at dosages even lower than that used in the present study.
Key words: Human studies: Oral ATP administration
Next to its intracellular role as an energy carrier, ATP and
its metabolites function extracellularly as the main ligands
involved in purinergic signalling. Purinergic signalling is
important for the regulation of inflammation, muscle con-
traction, neurotransmission and nociception (see Bours
et al. and Burnstock(1–3) for recent reviews). Modulation
of purinergic signalling by administration of purine recep-
tor antagonists (e.g. clopidogrel(4)) or by intravenous
administration of ATP or adenosine(5,6) has been shown
to effectively modulate human health.
Despite the small number of studies on the effectiveness
of oral ATP administration to modulate purinergic signal-
ling, capsules and tablets containing ATP at dosages
between 90 and 250 mg/d are being marketed on the Inter-
net as being highly efficacious. Capsules containing 30 mg
ATP are presently registered in France (Ate´pade`new) as an
adjunct in the treatment of low back pain of muscular
origin. In the late 1980s, two randomised, double-blind,
placebo-controlled trials were published in non-indexed
medical journals, showing that administration of 90 mg
Ate´pade`new was safe(7,8). In a recent double-blind trial,
the efficacy of Ate´pade`new for 1 month compared with
placebo was investigated in patients with low back
pain(9), while in an open-label trial, the same drug was
tested against the advice to stay active(10). Both trials indi-
cated that oral ATP had a modest benefit on a secondary
end point (the use of rescue analgesics) compared with
the non-pharmacological treatment. No differences
between ATP and placebo groups were found when con-
sidering pain or functional status of the patients. The inves-
tigators also noted that in the non-blinded trial, the positive
effect might largely be explained by the patients’ knowl-
edge of receiving a drug(9,10).
In order to investigate the bioavailability of oral ATP, we
previously conducted a study in which an acute oral dose
of ATP was administered as an enteric-coated multi-
particulate formulation designed to release its contents
in the proximal small intestine (further referred to as
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Abbreviation: DAUC, change in area under the curve.
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‘pellets’)(11). This single dose of ATP pellets did not result
in any increase in blood concentrations of ATP or of its
metabolites except uric acid. The results remained similar
when ATP was administered directly into the duodenum
via a naso-duodenal tube. We concluded from this study
that a single dose of oral ATP at the given dosage is not
effectively taken up. So far, the oral bioavailability of ATP
after prolonged administration (as recommended for oral
ATP supplements on the Internet) has only been studied
in animals. In experimental studies, contrary to expec-
tations, basal plasma ATP levels in animals treated with
5 mg orally administered ATP per kg for 30 d were lower
than those in water-treated control animals, suggesting a
potential up-regulation of ATP-metabolising enzymes in
plasma over the 30 d study. A similar effect was found
when oral ATP doses of 1, 5 or 10 mg/kg were given for
20 d. Interestingly, when a single dose of 14C-labelled
ATP was administered directly into the lumen of the jeju-
num of the rats treated with ATP for 30 d, a rapid 1000-
fold increase in portal plasma ATP concentration was
found compared with the control rats(12). The authors
suggested this to be the result of breakdown of ATP to ade-
nosine by intestinal nucleotidases, followed by increased
absorption of adenosine by nucleoside transporters present
in the intestinal membrane, in combination with an
increased efflux of ATP and nucleosides from intestinal
cells into the blood stream. Several nucleoside transporters
are now known, belonging to two families of concentrative
and equilibrative nucleoside transporters(13). To test
whether such an adaptive metabolic response to chronic
ATP administration as observed in animals might also
occur in humans, we set out to study this in healthy
human volunteers.
The present study had two specific objectives: first, to
establish whether whole blood and plasma concentrations
of ATP and its degradation products are influenced by oral
administration of 0, 250, 1250 or 5000 mg ATP per d for 4
weeks in healthy human subjects; and second, to investi-
gate whether 4 weeks of oral ATP administration leads to
adaptations in uptake, metabolism and excretion of a
single acute 5000 mg dose of ATP. Adverse events were
registered and safety was monitored by measuring a set
of liver and kidney blood parameters.
Materials and methods
Study design
A total of thirty-three subjects were assigned in a blinded
manner to one of four dosage groups by computer-
generated randomisation lists with a block size of eight.
On days 1–27, subjects were instructed to ingest enteric-
coated pellets twice a day, delivering a daily dose of ATP
of either (a) 5000, (b) 1250, (c) 250 or (d) 0 mg (placebo).
On days 0 and 28, all the subjects received a single dose of
5000 mg ATP as enteric-coated pellets. Subjects ingested
the pellets with approximately 200 ml of water that had
been acidified to a pH between 1 and 5.
Participants
Healthy male and female volunteers were recruited.
Exclusion criteria were: history of lung, heart, intestinal,
stomach or liver disease, use of prescription medication
(except contraceptives), smoking, drug use, dietary restric-
tions and pregnancy. Furthermore, only subjects aged
18–60 years could participate. To minimise between-
subject variation, the subjects were requested to abstain
from products containing alcohol or caffeine as well as
from purine-rich foods, such as game, offal, sardines,
anchovies and alcohol-free beer for 2 d before test days 0,
7, 14, 21 and 28. Subjects were asked to fast from 22.00
hours the previous day until the end of test days 0 and 28
(16.00 hours) and to refrain from any vigorous physical
activity 24 h before each test day. On days 0 and 28, subjects
were allowed to drink water starting 30 min after ATP
administration. On all intervening days, the subjects were
instructed to ingest the pellets at two self-chosen moments
during the day, each one either at least half an hour before
or 2 h after a meal. The present study was conducted
according to the guidelines laid down in the Declaration
of Helsinki, and all procedures involving human subjects
were approved by the Ethics Committee of Maastricht
University Medical Centre, The Netherlands. A written
informed consent was obtained from all the subjects.
Materials
ATP disodium salt and adenosine were purchased from
Fagron BV, Uitgeest, The Netherlands. ADP disodium salt,
AMP Na salt, adenine, inosine, hypoxanthine, uric acid
and perchloric acid 70 % solution in water were purchased
from Sigma Chemical Company (St Louis, MO, USA). KOH,
KH2PO4, K2CO3, K2HPO3·3H2O and NaOH were obtained
from Merck (Darmstadt, Germany) and 0·9 % saline was
purchased from Braun (Melsungen, Germany).
Production of pellets
Pellets were obtained from the laboratory of Pharma-
ceutical Technology, Ghent University, Ghent, Belgium.
ATP pellets were produced as described by Huyghebaert
et al.(14), with minor modifications to obtain an ATP con-
tent of .40 % (w/w) after coating. Placebo pellets were
produced in the same manner, but without ATP. The pellets
were coated with 30 % Eudragitw L30D-55 (Ro¨hm Pharma,
Darmstadt, Germany) and mixed with anionic copolymers
of methacrylic acid and ethyl acrylate (1:1). After coating,
the pellets were cured overnight at room temperature at
60 % humidity, packed in sealed double-plastic bags and
stored at 48C. Pellets were used within 3 months after pro-
duction. To ensure blinding of all personnel involved in
E. J. C. M. Coolen et al.358
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the study, a separate person not otherwise involved in the
study mixed the ATP and placebo pellets at proportions
needed to obtain the different doses (0, 250, 1250 and
5000 mg ATP/d), packaged and sealed the pellets in small
plastic bags each containing one daily dose and coded
them with subjects’ identification numbers according to
the randomisation list.
Dissolution testing
The pellets underwent quality control using a dissolution
test as described before(11). This test confirmed that the dis-
solution properties of the pellets were similar to those used
in our previous study(11). The release of ATP or degra-
dation products after 120 min in 0·1 M-HCl was ,3 %.
Subsequent transfer to a buffer solution of pH 6·5 caused
a release of 50 % of the remaining ATP within 10 min,
which increased to .90 % after 60 min (data not shown).
Sample collection
On days 0 and 28, subjects arrived at the study facility
(Maastricht University Medical Centre) at about 08.00
hours. Venous blood was collected from the antecubital
vein using a 20-gauge intravenous catheter (Terumo-
Europe NV, Leuven, Belgium) connected to a three-way
stopcock (Discofixw; Braun Melsungen AG, Melsungen,
Germany). Blood was collected into 4 ml EDTA tubes
(Venosafe, Terumo-Europe NV) by inserting a 21-gauge
multisample needle (Venoject Quick Fit, Terumo-Europe
NV) into the membrane of a closing cone (IN-Stopper;
Braun Melsungen AG) that was attached directly to the
stopcock. The anticoagulant EDTA inhibits the extracellular
hydrolysis of ATP by Ca2þ- and Mg2þ-activated enzymes,
such as plasma membrane-bound CD39(15). Serum tubes
were used to collect the samples for the assessment of
safety parameters (see later for details). After blood collec-
tion, the tubes were gently inverted three times and put on
ice. For whole blood measurements, 500ml EDTA blood
was immediately added to 500ml ice-cold perchloric acid
(8 %, w/v), vortex-mixed and frozen in liquid N2. For
plasma ATP determination, every second sample of EDTA
blood was diluted 1:2 with FireZyme Dilution Buffer (Bio-
Medica Diagnostics, Inc., Windsor, NS, Canada) and
immediately centrifuged at 3000g for 10 min at 48C. All
the blood samples were stored at 2808C awaiting analysis.
On days 7, 14 and 21, single samples of venous blood
were collected into EDTA tubes for whole blood ATP
determination. For the experiments on days 0 and 28,
baseline blood was sampled 30, 20 and 10 min before
administration of 5000 mg ATP to all thirty-two subjects.
Between 30 and 210 min after ATP administration, blood
samples were taken every 15 min, and between 210 and
420 min, samples were taken every 30 min. Urine was col-
lected 20 min before and 120, 220 and 400 min after ATP
administration, stored on ice before being frozen in
2808C at the end of the day. The total urine volume at
each time point was determined and each sample was
stored separately.
ATP measurement in whole blood samples by HPLC
Equipment, sample preparation and measurement con-
ditions for the determination of ATP and its metabolites
ADP, AMP, adenosine, adenine, inosine, hypoxanthine
and uric acid have been previously described and vali-
dated(16). Briefly, after thawing, the protein fraction was
precipitated (12 000g, 10 min, 48C) and 40ml 2 M-K2CO3
in 6 M-KOH was added to 650ml of the supernatant to neu-
tralise the pH. The resulting insoluble perchlorate was
removed by centrifugation (12 000g, 10 min, 48C) and
40ml of supernatant was mixed with 160ml of 0·05 M-phos-
phate buffer (pH 6·0) in HPLC vials. The compounds were
quantified with HPLC by UV detection at 254 nm.
ATP measurement in plasma samples
The diluted plasma samples were thawed and a CellTiter-
Glow ATP-assay kit (Promega Benelux BV, The Hague,
The Netherlands) was used according to the manufac-
turer’s instructions to measure the bioluminescence on a
Glomax plate reader.
Uric acid and creatinine measurement in urine samples
Urine samples were thawed and uric acid and creatinine
levels were measured using an automated analyser
(Beckman-Coulter, Sharon Hill, PA, USA). Uric acid con-
centration was corrected for creatinine by dividing the
uric acid concentration by the creatinine concentration.
Safety parameters
In order to assess the safety of a 4-week period of daily
administration of pellets containing up to 5000 mg ATP,
concentrations of creatinine, alkaline phosphatase, alanine
aminotransferase, lactate dehydrogenase and creatine
kinase were measured in undiluted serum samples using
a Beckman Synchron CX5 (Beckman Instruments, Inc.,
Gladesville, CA, USA) automatic analyser.
Statistical analysis
Results are reported as means and standard errors. Fasting
whole blood ATP and metabolite concentrations were cal-
culated from one sample taken in the morning on days 7,
14 and 21 and from the average of three samples taken at
30, 20 and 10 min before administration on days 0 and 28.
The change in area under the curve (DAUC) from the
fasting concentration on day 0 was calculated using the
trapezoidal rule for each subject for the 28 d period.
DAUC on days 0 and 28 during the 420 min following
Prolonged oral ATP administration 359
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ATP administration were calculated relative to baseline
values on the same day. For uric acid in urine and for
plasma ATP, the AUC was calculated using the trapezoidal
rule. Differences in DAUC or AUC between dosage
groups were evaluated with one-way ANOVA, and a least
significant difference post hoc test when appropriate.
Differences in response to 5000 mg ATP between days 0
and 28 were evaluated with a paired t test. All the
analyses were performed using SPSS 17.0 (SPSS, Inc.,
Chicago, IL, USA), and P,0·05 was considered statistically
significant.
Results
Study population
A total of thirty-two healthy volunteers (thirteen men and
nineteen women) completed the 4-week intervention
study. Men were on average 28·8 (SEM 14·1) years old
and weighed 69·4 (SEM 9·2) kg with a BMI of 21·8 (SEM
1·5) kg/m2 while women were on average 21·7 (SEM 4·6)
years old and weighed 66·7 (SEM 6·5) kg with a BMI of
22·8 (SEM 1·6) kg/m2. One female participant (assigned to
the placebo group) dropped out of the study because of
repeated vomiting after ingesting the pellets. All other
subjects tolerated the daily administration generally well.
Temporary nausea without vomiting occurred in two
women between 120 and 135 min after ingestion of the
first 5000 mg dose of ATP on day 0 of the study. Other
minor remarks included a bad taste of the pellets (n 1)
and a diminished appetite (one female subject from the
highest dosage group).
ATP and metabolites in whole blood
No significant change in fasting whole blood ATP concen-
tration occurred over the entire 4-week intervention
period, using doses of 0–5000 mg/d of ATP (Table 1).
Administration of a single oral dose of 5000 mg ATP on
days 0 and 28 of the study also did not lead to increased
ATP concentrations in whole blood during the 420 min fol-
lowing administration in any of the groups, and there was
no difference in response to ATP between days 0 and 28
(data not shown). The concentrations of adenosine and
other metabolites, except uric acid, were not increased
after oral administration (data not shown). Uric acid con-
centrations increased significantly over the 4-week
period, and this was only observed in the 5000 mg
dosage group v. the 0, 250 and 1250 dosage groups
(Table 1). On days 0 and 28, administration of a single
dose of 5000 mg ATP increased uric acid concentrations
on average up to 40 % above fasting concentrations
(Fig. 1). Uric acid concentrations started to increase at
approximately 30 min after ATP administration, and
levelled off at approximately 150 min until at least
300 min after ATP administration. The DAUC for uric acid
over the 420 min period following administration of the
single dose of 5000 mg ATP did not differ significantly
between days 0 and 28 nor between dosage groups
(Table 2).
Plasma ATP
Fig. 2 shows that plasma ATP concentrations after adminis-
tration of 5000 mg ATP on days 0 and 28 did not differ
significantly between the different dosage groups
(P¼0·42 for day 0 and P¼0·47 for day 28), nor between
days 0 and 28 (P.0·05).
Uric acid and creatinine in urine
Analysis of urine samples collected on days 0 and 28 of the
study revealed no clear upward or downward trend in uric
acid concentrations relative to creatinine (Fig. 3). There
was no significant difference between days 0 and 28
Table 1. Whole blood concentrations of ATP and uric acid in overnight-fasted healthy subjects after oral administration of placebo, 250,
1250 or 5000 mg ATP per d as enteric-coated pellets for 4 weeks
(Mean values with their standard errors)‡
Day 0 Day 7 Day 14 Day 21 Day 28 DAUC*
Dosage (mg) Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
ATP concentrations (mM)
0 407 59 382 64 423 72 544 125 395 66 209 1240
250 350 45 370 44 357 39 397 26 364 32 291 760
1250 419 36 410 32 420 39 415 37 361 39 2200 326
5000 388 42 386 36 406 27 396 32 351 31 754 723
Uric acid concentrations (mM)
0 297 35 266 20 298 31 418 88 286 30 364 828
250 290 26 319 15 324 14 420 68 302 18 496 464
1250 337 29 365 31 346 33 362 12 316 22 1 177
5000 269 16 348 18 357 25 436 55 317 11 2536† 694
AUC, area under the curve; LSD, least significant difference.
* Mean values were significant overall in AUC between dosage groups for uric acid (P¼0·02), but not for ATP (P¼0·83, ANOVA).
† Mean values were significant for dose of 5000 mg from 0, 250 and 1250 mg dosage groups (P,0·03, post hoc LSD-test).
‡ Values of eight subjects/dosage group.
E. J. C. M. Coolen et al.360
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within each dosage group (P.0·10 for all dosage groups).
Within days 0 and 28, there were no differences between
the dosages of ATP (P¼0·92 on day 0 and P¼0·22 on
day 28).
Safety parameters
As shown in Table 3, none of the safety parameters chan-
ged in response to administration of up to 5000 mg ATP for
4 weeks and all median concentrations remained in the
reference range for healthy volunteers. Although we
observed some individual values for alkaline phosphatase,
lactate dehydrogenase and creatine kinase above the refer-
ence range, this occurred to a similar extent at baseline (i.e.
before ATP/placebo administration) and after 28 d, and
also occurred to a similar extent in the placebo and the
highest ATP dose group (Table 3).
Discussion
In this randomised, double-blind, placebo-controlled trial,
we investigated the effects of a 4-week period of daily
oral ATP administration. The first objective of the present
study was to assess whether prolonged daily oral adminis-
tration of ATP would lead to increased blood and plasma
concentrations of ATP and its degradation products. Even
after 4 weeks of oral administration, we detected no rise
in concentrations of ATP or any of its metabolites, except
for uric acid, which showed a significant overall increase
in the highest ATP dosage group compared with the
other dosage groups over the 4-week period.
Our findings partly agree with previous studies con-
ducted in rats (5 mg/kg per d for 30 d) and rabbits
(20 mg/kg per d for 14 d) by Kichenin et al.(12,17), who
found no increase in erythrocyte ATP and adenosine
concentrations. However, these authors even reported a
decrease in basal plasma ATP concentrations in rats
receiving 5 mg/kg per d for 30 d(12). High-dose oral ATP
administration trials in human subjects have not been
reported before. In oneprevious trial, healthymales ingested
much lower doses of ATP (0, 150 or 225 mg/d) for 14 d.
No significant increase in ATP levels was observed and
no other metabolites were measured in that human trial(18).
It is known that ATP is quickly metabolised in the small
intestine. First, ecto-nucleotidase triphosphatase dipho-
sphohydrolases present on the luminal side of enterocytes
dephosphorylate ATP via ADP to AMP(19). Secondly, AMP
is also not likely to stay intact in the small intestine, since
ecto-50-nucleotidase (CD73) and alkaline phosphatases
degrade it to adenosine(20). Adenosine can be transported
to the intestinal villi and into erythrocytes by nucleoside
Dosage on days 1–27: placebo
Dosage on days 1–27: 1250 mg
Dosage on days 1–27: 250 mg
Dosage on days 1–27: 5000 mg
U
ri
c 
ac
id
 in
cr
ea
se
 f
ro
m
 b
as
el
in
e 
(%
)
40
30
20
10
0
–10
40
30
20
10
0
–10
30 60 90 120 150 180 210 240 270 300 330 360 390 420 30 60 90 120 150 180 210 240 270 300 330 360 390 420
Time after administration (min)
(a) (b)
(c) (d)
Fig. 1. Increase in whole blood uric acid concentration following an acute oral bolus of 5000 mg ATP as enteric-coated pellets to healthy subjects (n 8 for each
dosage group). On days 1–27, subjects received placebo (a), 250 mg/d ATP (b), 1250 mg/d ATP (c) or 5000 mg/d ATP (d). , day 0; , day 28.
Table 2. Change in area under the curve from baseline (DAUC) for
whole blood uric acid concentrations on days 0 and 28, after a single
oral dose of 5000 mg ATP as enteric-coated pellets
(Mean values with their standard errors)*
Day 0 Day 28
Dosage (mg) Mean SEM Mean SEM P†
0 5484 518 5321 520 0·828
250 5364 433 5487 320 0·820
1250 6076 426 5965 423 0·857
5000 5403 165 4780 244 0·166
P 0·337 0·613
* Values of eight subjects/dosage group.
†P values are calculated by paired samples t tests across days and by one-way
ANOVA across dosages.
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transporters(21). We suggest that the enzymes adenosine
deaminase (present in endothelial cells) and xanthine oxi-
dase (present in the liver) efficiently degraded adenosine
to uric acid(22). This could explain our observation that
exclusively uric acid was found to be increased during
ATP administration. This increase in uric acid, but not in
ATP or other metabolites, upon administration of a single
dose of 5000 mg ATP is in accordance with our earlier
findings(11). Uric acid has an elimination half-life of
approximately 20 h(23). Indeed, the uric acid concentration
we observed in the present study did not decline much
during 6 h after administration of 5000 mg ATP. Since
pellets were ingested twice a day from days 1 to 27, the
periods between ATP ingestion were close to 12 h; there-
fore, partial transfer of uric acid from the last dosage
from the previous day may have contributed to the
A
T
P
 in
 p
la
sm
a 
(n
M
)
30–30 0 60 90 120 150 180 210 240 270 300 330 360 390 300–30 60 90 120 150 180 210 240 270 300 330 360 390
Time before/after administration of 5000 mg ATP (min)
Dosage on days 1–27: placebo (n 6) Dosage on days 1–27: 250 mg (n 6)
Dosage on days 1–27: 1250 mg (n 6) Dosage on days 1–27: 5000 mg (n 6)
2000
1500
1000
500
0
2000
1500
1000
500
0
(c)
(a)
(d)
(b)
Fig. 2. Plasma ATP concentrations following an acute oral bolus of 5000 mg ATP as enteric-coated pellets to healthy subjects. ATP was administered at t ¼ 0 (n 6 or
4 per dosage group). On days 1–27, subjects received placebo (a), 250 mg/d ATP (b), 1250 mg/d ATP (c) or 5000 mg/d ATP (d). , day 0; , day 28.
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Fig. 3. Concentrations of uric acid relative to creatinine in urine following an acute oral bolus of 5000 mg ATP as enteric-coated pellets to healthy subjects (n 8 for
each dosage group). On days 1–27, subjects received placebo (a), 250 mg/d ATP (b), 1250 mg/d ATP (c) or 5000 mg/d ATP (d). Error bars represent standard
deviation. , day 0; , day 28.
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Table 3. Serum concentrations of five safety parameters in samples collected 20 min before (t ¼ 220) or 105 min (t ¼ 105) after oral administration of 5000 mg ATP as enteric-coated pellets to healthy
subjects
(Median values and ranges)*
Dosage on days 1–27
Placebo 250 mg 1250 mg 5000 mg
t ¼ 220 min t ¼ 105 min t ¼ 220 min t ¼ 105 min t ¼ 220 min t ¼ 105 min t ¼ 220 min t ¼ 105 min
Median Range Median Range Median Range Median Range Median Range Median Range Median Range Median Range
Day 0
Creatinine† 85 62–97 75 59–90 83 64–103 78 63–97 85 67–99 81 71–97 85 65–91 77 63–94
Alkaline
phosphatase†
58 37–140 57 41–145‡§ 74 57–112 70 57–119 61 37–93 62 35–84 44 35–68 45 29–67
ALAT† 12 9–19 16 12–20 13 6–39 16 10–40 17 5–19 12 7–17 12 3–16 12 4–16
LD† 289 271–468 340 272–570§ 344 241–437 373 320–754‡k 380 222–767‡§ 362 298–447 349 255–511‡§ 339 251–407
CK† 65 35–162 62 31–155 83 36–287 139 42–277 67 39–152 74 38–150 74 42–90 86 39–123
Day 28
Creatinine† 76 59–103 75 58–92 78 66–109 74 66–106 86 71–98 84 68–94 79 62–99 76 64–93
Alkaline
phosphatase†
49 40–140 48 36–141 80 58–106 77 60–108 54 34–70 54 36–66 67 31–79 50 35–78
ALAT† 14 11–25 11 5–27 16 6–41 16 5–37 18 8–21 13 11–17 13 10–21 14 5–18
LD† 319 244–555‡k 320 236–510‡§ 417 291–609‡{ 366 283–527‡§ 395 291–451 354 213–440 349 222–647‡§ 397 306–564‡§
CK† 54 33–241 54 30–220‡k 66 37–329‡{ 61 39–180 99 61–121 82 34–138 94 46–167 86 44–124
ALAT, alanine amino transferase; LD, lactate dehydrogenase; CK, creatine kinase.
* Eight subjects/dosage group.
† The reference values are as follows: creatinine 60–115mmol/l (male), 50–100mmol/l (female); alkaline phosphatase ,140 IU/l; ALAT ,45 IU/l (male), ,35 IU/l (female); LD ,480 IU/l; creatine kinase ,225 IU/l (male), ,160 IU/l
(female) (reference values and full names of the parameters apply to healthy volunteers).
‡ An individual maximum value exceeded the reference value.
§ The number of individuals with higher than maximum values (n 1).
kThe number of individuals with higher than maximum values (n 2).
{The number of individuals with higher than maximum values (n 4).
P
ro
lo
n
g
e
d
o
ral
A
T
P
ad
m
in
istratio
n
3
6
3
British Journal of Nutrition
observed rise in basal uric acid concentrations on days 7,
14, 21 and 28 (Table 1). The implications of this increase
in uric acid concentration are discussed later.
Our second objective was to investigate whether the
uptake, metabolism and excretion of an acute oral ATP
bolus would be influenced by prolonged administration
(4 weeks) of 250, 1250 or 5000 mg/d of oral ATP. For this
purpose, we performed an experiment with a single
acute dose of 5000 mg ATP on day 0 and repeated this
experiment in all subjects on day 28. Results showed
that, again, only the concentrations of uric acid, and not
of ATP or any of the other metabolites, increased immedi-
ately after the single dose of 5000 mg ATP. Furthermore,
there were no significant differences in concentration
changes between days 0 and 28 for any of the measured
compounds. Although NS, the data presented in Table 2
and Fig. 1(d) suggest that in the highest dosage group
(5000 mg ATP), the rise in uric acid concentrations in
response to administration of 5000 mg ATP on day 28
was smaller than on day 0. Since we found no increase
in uric acid excretion in the urine samples collected on
day 28 (Fig. 3), a more efficient excretion of uric acid is
not likely to be the cause.
Previous studies in animals showed that, while systemic
concentrations did not change, concentrations of ATP and
its metabolites in the portal vein increased after prolonged
ATP administration. Clearly, in our healthy volunteers, we
could not sample portal blood to clarify the intestinal fate
of ATP(12).
With the present study, we intended to explore whether
oral administration of ATP by enteric-coated pellets could
be used as an alternative to other means of ATP adminis-
tration. Intravenous administration of ATP has been
described to elicit marked health benefits and promote sur-
vival in cancer patients(5,6,24–31). Although it is feasible to
intravenously administer ATP at home, some drawbacks
include the increased risk of side effects, difficulty of
achieving venous access and the need for medical supervi-
sion(5,6,24–31). Previous studies with oral administration of
ATP have employed either ATP in solution or relatively
large enteric-coated capsules. The latter has the drawback
of being difficult to target a specific area of the small
intestine due to gastric retention and unreliable enteric
coating(18). In the present study, we prevented these
problems by using small enteric-coated pellets with a
well-defined release profile, which in addition was tested
in pilot experiments. Although the pellets were well
tolerated and did release their contents, we could not
demonstrate any increase in systemic ATP levels in contrast
with intravenous ATP administration.
The present results have important implications. First,
the reported efficacy of oral ATP supplements that are
available through web stores or as registered drugs
should be reconsidered. As we find no change in whole
blood ATP concentrations at dosages several times exceed-
ing the dosages administered via currently used oral ATP
supplements, the present results justify the strong doubts
regarding the claims on these supplements as being effec-
tive in providing ATP to the body. Secondly, the observed
increases in uric acid concentrations in the present study
may well explain some of the physiological effects
reported after oral ATP administration in previous studies.
Uric acid has a controversial reputation: it is at the same
time thought to be (1) an important physiological antioxi-
dant that reduces oxidative stress, (2) a normally innocent
metabolic waste product that only causes gout or kidney
stones if present in excessively high concentrations and
(3) a causal factor for hypertension, obesity and vascular
and renal diseases(32–35). With regard to the first hypoth-
esis, there are indications that uric acid may have
anti-inflammatory activities in conditions such as multiple
sclerosis, Parkinson’s disease and acute stroke(36–38).
These may be partly due to the strong antioxidant capacity
of uric acid. The use of oral ATP-containing supplements to
increase uric acid concentrations might be of therapeutic
value for these diseases. Secondly, the pro-inflammatory
properties of uric acid crystals have long been known to
be involved in gout. The uric acid deposits that occur pre-
dominately in joints after prolonged periods of excessively
high concentrations of uric acid can eventually trigger an
inflammatory response(39). Uric acid is also known to act
as a ‘danger signal’, when it is released from necrotic
cells(40). Hyperuricaemia is often defined as uric acid
.71 mg/l (420mmol/l) in men and .61 mg/l (360mmol/l)
in women(41,42). In the present study, the blood concen-
trations of uric acid stayed below these values. Our data
on creatinine, alkaline phosphatase, alanine aminotransfer-
ase, lactate dehydrogenase and creatine kinase also
demonstrate that daily administration of 5000 mg ATP is
safe. As for the third hypothesis, given the complex
relationship of uric acid with other established cardiovas-
cular risk factors, such as obesity, the metabolic syndrome,
diabetes and especially hypertension, and due to the lack
of prospective studies, it remains unclear whether uric
acid is indeed a causal factor for these conditions(43,44).
In conclusion, the present study shows that a 4-week
period of daily administration of ATP as enteric-coated
pellets does not lead to increased plasma or blood ATP
concentrations, nor is there any evidence of a metabolic
adaptation in the uptake or metabolism of ATP. The
present results cast serious doubt on the health claims of
oral ATP supplements.
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